Orthofix International Announces Third Quarter Results And Additional Debt Payment Ahead of Scheduled Maturity

Share this story with your network

  • Q309 sales totaled $135.1 million, up 4% from Q308; up 7% on a constant currency basis
  • Sales of spinal implants & biologics were up 10%, to $28.5 million, vs. prior year; sales of spine stimulation products grew 12%, to $39.6 million
  • Sales in the orthopedic business decreased 2%, but increased 6% on a constant currency basis
  • Sales in the sports medicine business grew 4% in total, to a record $24.7 million; U.S. sales increased 6%
  • Consolidated gross margin improved to 76.3%; operating margin increased to 13.1%
  • Q309 reported net income was $0.36 per diluted share; excluding certain items, adjusted net income was $0.44 per diluted share
  • The Company made an additional $5 million debt payment ahead of schedule maturity in October

Leave a Comment

Your email address will not be published. Required fields are marked *